Day Zero Diagnostics Announces Completion of $21M Financing
February 8 2022
Funding development of a disruptive whole-genome sequencing-based diagnostic system for bloodstream infections
Read More
Day Zero Diagnostics Wins the New Life Sciences Diagnostic Category at the Annual UCSF Health Awards
October 11 2021
Pioneering a New Class of Culture-free, Sequencing Diagnostics to Help Patients with Severe Infections
Read More
DZD Wins Disruptive Technology Award at the 2021 AACC Annual Scientific Meeting
September 30 2021
Award Highlights the Promise of the Company’s New Class of Diagnostics
Read More
DZD Doubles Down on epiXact® Service for Investigating HAI Outbreaks Supported by New NIH Funding Award
December 9 2020
SBIR Phase I Funds to Boost Speed of the Company’s Robust Sequencing and Analysis Service for Infection Control Professionals
Read More
DZD Announces High-Caliber Additions to Leadership Team and Advisory Board
November 17 2020
Dekel Gelbman joins as SVP, Business Development & Strategy, Robin Patel, M.D. joins DZD's clinical and scientific advisory board and Sally Hojvat, Ph.D. joins as a regulatory strategy advisor
Read More
Day Zero Diagnostics Moves Headquarters to SmartLabs at Boston Landing
August 3 2020
Company now occupies over 9,000 square feet of cutting-edge office and lab space
Read More